ERBB2 and neoplasm: With regard to tumour site, 5-year survival in OC HER2 positive versus negative cohorts was 100% and 36% (P = 0.167) compared with 14% and 44% (P = 0.0726) in JC (Figure 2) and 50% and 46% (P = 0.942) in GC, respectively.